Brief: TC Biopharm Announces FDA Orphan Drug Status Granted For Omnimmune®
17/03/2022 13:41
March 17 (Reuters) - TC BioPharm Ltd T0Uy.F :
* TC BIOPHARM ANNOUNCES FDA ORPHAN DRUG STATUS GRANTED FOR
OMNIMMUNE®
Source text for Eikon: ID:nPn83lN8Da
Further company coverage: T0Uy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TC Biopharm (Holdings)
See all newsBrief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: TC BioPharm Announces Complete Response In Minimal Residual Disease Patient
Brief: TCBP Announces Non-Binding Letter Of Intent To Acquire Commercial Stage Ophthalmic Pharmaceutical Company
Brief: TC Biopharm's Data Show A Favorable Response In Patients With Relapse Or Refractory AML
Brief: TCBP Trading Continues Unabated On Nasdaq Stock Exchange